Clinical trials
Hyperphosphatemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 4 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Terminated | 6 |
| Recruiting | 4 |
| Unknown status | 3 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ardelyx | 6 |
| Keryx Biopharmaceuticals | 5 |
| Denver Nephrologists, P.C. | 3 |
| Fresenius Medical Care North America | 3 |
| Genzyme, a Sanofi Company | 3 |
| Ineos Healthcare Limited | 3 |
| Duke University | 2 |
| Nabi Biopharmaceuticals | 2 |
| Shire | 2 |
| Tanabe Pharma Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperphosphatemia | 55 |
| Kidney Failure, Chronic | 18 |
| Renal Insufficiency, Chronic | 16 |
| Renal Insufficiency | 10 |
| Kidney Diseases | 5 |
| Anemia, Iron-Deficiency | 3 |
| Cardiovascular Diseases | 3 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 |
| Heart Failure | 2 |
Trials
Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.